Otsuka Chemical Succeeded Part of the Cefixime Business from Astellas Pharma
Otsuka Chemical Co., Ltd. (Head office: Chuo-Ku, Osaka; President & Representative Director: Takeharu Harashima; hereinafter “Otsuka Chemical”) announces that it has succeeded part of the Cefixime business from Astellas Pharma, Inc. (Head Office: Chuo-Ku, Tokyo; President & CEO: Kenji Yasukawa, Ph.D.; hereinafter “Astellas Pharma”).
Through this agreement, Otsuka Chemical acquires the business of Cefixime from Astellas Pharma to supply the API (Active Pharmaceutical Ingredient) to overseas licensees along with assets such as contracts belonging to the licensing business and the trademark. This means our company’s entry into the API business, resulting in strengthening the integrated antibiotic-related business from intermediates to API.
Cefixime developed by Astellas Pharma is a third-generation cephalosporin with antibacterial activity against gram-positive and gram-negative bacteria and it is extensively prescribed worldwide.
In addition to the main business field of chemicals, Otsuka Chemical will continue strengthening the manufacturing technology of high-quality API and their marketing and brand power to promote pharmaceutical-related business and CMO business by taking advantage of key technologies cultivated in the field of organic and inorganic chemicals.
|Otsuka Chemical Co., Ltd.|
|Established||:||August 29, 1950|
|Capital||:||5 billion yen|
|President||:||Takeharu Harashima, President and Representative Director|
|Head Office||:||3-2-27, Ote-Dori, Chuo-Ku, Osaka, 540-0021 Japan|
|Employees||:||1,857 (consolidated; as of December 31, 2018)|
Manufacturing and sales of chemical products
Astellas Pharma Inc.
|Capital||:||103 billion yen|
|President||:||Kenji Yasukawa, President and CEO|
|Head Office||:||2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan|
|Employees||:||16,243 (consolidated; as of March 31, 2019)|
|Research and development, manufacturing, and sales of pharmaceuticals|
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
CA-C3.AI20.6.2019 23:18:11 CEST | Pressemeddelelse
C3.ai Named a Leader in Worldwide Industrial IoT Platforms for Energy by IDC MarketScape
MA-HOLOGIC-INC20.6.2019 22:03:06 CEST | Pressemeddelelse
Hologic Enters into Exclusive Negotiations to Acquire SuperSonic Imagine, French Ultrasound Innovator
MA-PTC20.6.2019 19:56:09 CEST | Pressemeddelelse
Digital Transformation Gets Bigger, Better, Bolder at LiveWorx’19
INSERT-ARCH20.6.2019 18:49:05 CEST | Pressemeddelelse
INSERTING and REPLACING Arch Capital Group Names Seamus Fearon EVP, Credit Risk Transfer and Services, Global Mortgage Group
BIOLOG-ID20.6.2019 17:37:11 CEST | Pressemeddelelse
The “Centre Hospitalier de la Côte Basque” in France Has Started the Evaluation of the Biolog-id’s C-LOG® Solution
DE-CSC20.6.2019 17:02:09 CEST | Pressemeddelelse
CSC Announces Cyber Security Findings for the Media Industry
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum